Frontier Medicines announced the advancement of lead candidates for further optimization in an AbbVie partnered program targeting a key transcription factor for cancer cell survival, triggering an accompanying milestone payment. Started in 2020, the objective of the global partnership is to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- ABBV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Options Volatility and Implied Earnings Moves This Week, July 22 – July 26, 2024
- AbbVie price target raised to $214 from $180 at BMO Capital
- AbbVie submits regulatory applications to FDA, EMA for upadacitinib
- AbbVie price target raised to $196 from $191 at Morgan Stanley